Lycopene as a Dietary Compliance Biomarker

August 4, 2025 updated by: Lionne Venderbos, Erasmus Medical Center

Plasma Lycopene Concentration as a Dietary Compliance Biomarker - a Pilot Study

Rationale: To determine the plasma lycopene concentration before and after an oral intake of lycopene in order to use this measurement as a life style compliance marker.

Objective: Primary objective: to determine if a plasma lycopene concentration can serve as a response parameter after a single dose of dietary lycopene.

Study design: Cross-over interventional pilot study.

Study population: Ten male healthy volunteers 18-75 years. Intervention: Oral food supplement tablet 40 mg lycopene once, versus oral soup of cooked tomatoes equivalent to 40 mg lycopene content. In addition, the participants' habitual diet and actual food intake during the intervention will be measured using a food frequency questionnaire and a food diary.

Main study parameters/endpoints: Variation of plasma lycopene 1 hour before, and 1,3,6,12,24,48,72 hours after intervention.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Eight blood samples of 6 ml full venous blood obtained by vena puncture per intervention per individual, 2 times in a cross-over pilot study, in which interventions are 3 weeks apart (so 2 x 8 samples in 10 volunteers). Risk of vena puncture is negligible, idemque the burden.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Rotterdam, Netherlands
        • Recruiting
        • Erasmus MC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male;
  • Healthy;
  • 18-75 yrs old.

Exclusion Criteria:

  • Allergic for tomatoes;
  • Any gastrointestinal disorder within 3 months prior to the intervention;
  • Recent medication or supplement use;
  • Recent substantial change in weight;
  • Adherence to a specific diet ( for example the Moorman-diet);
  • Using recreational drugs more than once a month;
  • Smoking and excessive alcohol consumption (>10 standardized glasses a week).
  • Risk of a dependency situation with the researchers.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A - supplement, tomato soup
Group A will take 40 mg lycopene (2,5 pills of food supplement Vitabiotics Ultra Lycopene 15mg, potent extract) first. After a wash-out period, group A will continue and take 250ml of tomato soup (matching with 40mg lycopene) with 20ml olive oil.
Group will take 40 mg lycopene (2,5 pills of food supplement Vitabiotics Ultra Lycopene 15mg, potent extract).
Group will take 250 ml of tomato soup (matching with 40 mg lycopene) with 20 ml olive oil.
Experimental: Group B - tomato soup, supplement
Group B will take 250 ml of tomato soup (matching with 40 mg lycopene) with 20 ml olive oil first. After a wash-out period, group B will continue and take 40mg lycopene (2,5 pills of food supplement Vitabiotics Ultra Lycopene 15mg, potent extract).
Group will take 40 mg lycopene (2,5 pills of food supplement Vitabiotics Ultra Lycopene 15mg, potent extract).
Group will take 250 ml of tomato soup (matching with 40 mg lycopene) with 20 ml olive oil.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To measure lycopene concentration after a single dose of dietary lycopene.
Time Frame: From enrollment until 72 hours after, wash out period of 3 weeks, then again start until 72 hours later.
From enrollment until 72 hours after, wash out period of 3 weeks, then again start until 72 hours later.

Secondary Outcome Measures

Outcome Measure
Time Frame
To measure lycopene concentration after taking a food supplement tablet lycopene of 40mg of lycopene.
Time Frame: Start intervention until 72 hours later, wash-out period, start intervention until 72 hours later.
Start intervention until 72 hours later, wash-out period, start intervention until 72 hours later.
To measure prior food consumption using a daily food questionnaire.
Time Frame: One week before the dietary intervention a daily food questionnaire will be completed.
One week before the dietary intervention a daily food questionnaire will be completed.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lionne DF Venderbos, Erasmus Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 11, 2025

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

July 25, 2025

First Submitted That Met QC Criteria

August 4, 2025

First Posted (Actual)

August 12, 2025

Study Record Updates

Last Update Posted (Actual)

August 12, 2025

Last Update Submitted That Met QC Criteria

August 4, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • MEC-2023-0633
  • NL85468.078.23 (Other Identifier: Erasmus MC)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Supplement

Subscribe